Led by Professor Graham Foster, this £2.7million Wellcome Trust Programme has been set up to describe the treatment efficacy of licensed therapy for Hepatitis C virus (HCV) in Pakistan, examine the impact of an expanded access test and treat program and, in collaboration with government and non-government programs, determine the most cost-effective way to eliminate HCV in Pakistan.
Welcome to HepFreePak
Our study sets out to characterise the incidence of new onset and re-infections with HCV, while assessing the risk factors associated with transmission of the virus.
At the same time, we are carrying out further analyses to establish the impact of resistance associated virus polymorphisms on treatment responses and hepatocellular carcinoma (HCC; liver cancer) occurrence.
Here you will be able to explore our studies in more detail, familiarise yourself with our team and hear our latest news.